Nintedanib in systemic sclerosis-associated interstitial lung disease: real-world cohort study on tolerability and discontinuation
Adverse effects frequently led to treatment interruptions in SSc-ILD patients. Older age and lower BMI were predictors of interruption, while no clear predictors of permanent discontinuation were identified. Most patients resumed treatment, highlighting the need for close monitoring and supportive care to manage side effects and maintain treatment continuity.
Authors
- P Sestini
- Arthihai Srirangan
- Punchalee Kaenmuang (ORCID: https://orcid.org/0000-0001-7877-0468)
- Carmel Stock (ORCID: https://orcid.org/0000-0003-4090-8761)
- B Vitri
- Fiammetta Danzo (ORCID: https://orcid.org/0000-0001-8833-3675)
- Ali Taki
- Wing-Ho Yip
- Athol U. Wells
- Elisabetta A. Renzoni
- Shereen Boreland
- Nina R. Goldman
- Christopher P. Denton
- Voon H. Ong
Institutions
- University of Siena (IT)
- National Health Service (GB)
- Royal Free London NHS Foundation Trust (GB)
- Royal Brompton Hospital (GB)
- Lung Institute (US)
- British Society for Rheumatology (GB)
- Center for Rheumatology (US)
- University College London (GB)
Publication Details
- Journal
- Clinical and Experimental Rheumatology
- Published
- 2025-08-25
- DOI
- https://doi.org/10.55563/clinexprheumatol/dvur8b
- Primary Topic
- Systemic Sclerosis and Related Diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00